6:21 PM
 | 
Aug 11, 2014
 |  BC Extra  |  Company News

MannKind licenses Afrezza to Sanofi

MannKind Corp. (NASDAQ:MNKD) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize Afrezza inhaled insulin to treat adults with Type I and II diabetes. MannKind will receive $150 million in cash up front and is eligible for up to $775 million in milestones. The milestones include $75 million in near-term manufacturing...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >